March 26, 2024 | Daily JAM, Jubak Picks, LLY, Mid Term, Morning Briefing, NVO, Stock Alerts, VKTX |
First, it was Viking Therapeutics (VKTX) on the attack with trial results that shows its GLP-1 dibetes/weight loss drug out performing current leader of the pack drugs fro Novo Nordisk (NVO) and Eli Lilly (LLY). On the news Viking soared.
Then Novo Nordisk struct back with data of its own showing progress on an oral formulation of its rugs. (All existing GLP-1 drugs are delivered by injection.) That cratered Viking Shares. Now, March 26, Viking has released new Phase 1 trial data from a multiple ascending dose study of the oral version of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
March 19, 2024 | Daily JAM, Dividend Income, EQNR, Jubak Picks, Mid Term, Special Reports, Top 50 Stocks, V |
Let’s say you’re a dividend income investor. You need cash income in retirement. Or you want your portfolio to generate cash now so you can invest in new opportunities. Or you just want the extra safety and lower risk that owning a stock with a substantial dividend can bring. Whatever your reasons–and I can think of a lot more–this is a particularly challenging financial market for dividend income investors.But I do think there are strategies dividend income investors can successfully pursue even in this challenging market. In the rest of this Special Report I’m going to explain the three ways I think you should be thinking about dividend income investing in this market. And then I’m going to give you 10 dividend stocks that I think are especially well-suited to producing income (and price appreciation, which is always nice even if you’re an income investor) in this market environment. First pick just posted–Pfizer
March 8, 2024 | Daily JAM, Jubak Picks, Mid Term |
Shares of Viking Therapeutics (VKTX) are down norther 6.22% as of noon today in New York. That comes after the stock dropped 18.84% yesterday. I think that the market thinking here by and large wrong and I’d use the big painful drop as an opportunity to buy more shares of Viking Therapeutics.
March 7, 2024 | Daily JAM, Jubak Picks, LLY, NVO |
Yes, I know this is my third post (plus video) on diabetes/weight-loss drug leader Novo Nordisk (NVO) in three weeks. But the company keeps pumping out research updates that keep powering the stock higher. Think of this as a momentum stock where the momentum comes from the R&D pipeline and not moves in the share price. (The last post was https://jubakam.com/another-reason-t…-success-for-glp/) Today, the company reported early results for a next-generation oral weight loss drug called amycretin, showing a 13.1% weight loss after 12 weeks. That’s a bigger weight-loss than either Novo Nordisk’s own Wegovy or Eli Lilly’s (LLY) competing drug Zepbound. Shares of Novo Nordisk were up 8.9% today to $135.85. I added them to my Jubak’s Picks Portfolio on February 20. The position is up 11.91% since then.
March 5, 2024 | Daily JAM, Jubak Picks, LLY, Morning Briefing, NVO, Volatility |
Back on February 20, I posted a video recommending a buy of Novo Nordisk (NVO). In the video, “Buy GLP-1,” I said that the stock, along with Eli Lilly (LLY) was riding the momentum of increased sales of GLP-1 drugs, originally developed to treat diabetes, as weight-loss drugs. Buy, I said, despite the huge run-up in the shares, because new trials and analysis of existing data were pointing to expanded uses for the drugs. Today, Novo Nordic announced exactly the kind of news that I had talked about.
February 29, 2024 | Daily JAM, Jubak Picks, Videos, Volatility |
Today’s Hot Button Moves NOW video is Buy Viking Therapeutics (VKTX). Last week I suggested that you buy GLP-1 drug stocks like Eli Lilly (LLY) or Novo Nordisk (NVO). This class of diabetes and weight loss drugs is growing rapidly, with $36.5 billion in sales in 2023. Viking Therapeutics, a development-stage biotech company, recently announced Phase 2 trial results for its compound VK2735. This drug has the potential to be the best in its class when it hits the market. The company still has to go through Phase 3 trials and approval, but the data show VK2735 to be more effective at weight loss than its competitors. It could also be one of the few drugs of its kind to be available orally. The current round of trials shows that the drug will need to be injected less frequently than competitors. The company trades with a market cap of $9 billion (in contrast to Lilly’s $720 billion market cap) and is still small enough that it could be bought before the expensive process of taking a drug to market. (Although the company recently raised a secondary offering that would advance marketing plans.) I would buy this up to $100 a share and expect it to continue to zoom as more good news, I expect, on the oral version gets released this quarter. I am adding the stock to my online portfolios today, Thursday, February 29. You can find a write up on this pick on my subscription JubakAM.com and free JubakPicks.com sites.
February 28, 2024 | Daily JAM, Jubak Picks, LLY, Stock Alerts, Volatility |
Yesterday, February 28, development-stage biotech Viking Therapeutics (VKTX) announced results from a Phase 2 training of its GLP-1 weight-loss drug candidate that that showed the potential for the VK2735 compound two move to be best in class in the $36.5 billion (revenue) market for GLP diabetes-control and weight-loss drugs. I will add Viking Therapeutic to my Volatility Portfolio and to my Jubak’s Picks Portfolio today, February 29, with a target price of $150.
February 27, 2024 | Daily JAM, Mid Term, Special Reports |
Can you have your cake and eat it too? That’s basically the question stock investors and traders face now. Is there a way to build a strategy that will put profits in your pocket if the rally that set in at the end of 2023 continues? And that will hedge the downside so the your portfolio won’t tumble if the market does? Or that will at least lose less? Or that might even make some money on its downside bets. I think there is. And that’s the subject of this Special Report. Today Steps 1-3
February 20, 2024 | Daily JAM, Jubak Picks, LLY, Videos |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
November 9, 2023 | Daily JAM, Jubak Picks, LLY, Stock Alerts |
On Wednesday the Food and Drug Administration approved Mounjaro from Lilly, as an obesity drug, after clinical trials showed that patients lost an average of 18% of their body weight. The drug will be marketed as Zepbound in the obesity market. This puts Lilly into direct competition with the wildly popular Wegovy weight-loss drug from Novo Nordisk (NVO)
June 15, 2015 | Daily JAM, Morning Briefing, Short Term, Volatility |
Why, you might well ask (and probably have) am I spending so much time tracking the ins and outs of the Greek debt crisis? Because in the short run this is exactly the kind of scary venture into completely uncharted territory—no country has ever left the euro and in fact an exit was never even contemplated when the euro was put together—that can produce a panicked plunge in asset prices
February 11, 2013 | Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
